Details for Patent: 11,186,547

Which drugs does patent 11,186,547 protect, and when does it expire?

Patent 11,186,547 protects LENVIMA and is included in one NDA.

Protection for LENVIMA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-nine patent family members in twenty-four countries.

Summary for Patent: 11,186,547

Title:	High-purity quinoline derivative and method for manufacturing same
Abstract:	Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less. ##STR00001##
Inventor(s):	Nakamura; Taiju (Kamisu, JP), Abe; Taichi (Kamisu, JP), Miyashita; Yusuke (Kamisu, JP), Kuroda; Hirofumi (Kamisu, JP), Ayata; Yusuke (Kamisu, JP), Akao; Atsushi (Kamisu, JP)
Assignee:	Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:	17/022,675
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 11,186,547

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No					Y
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-002	Feb 13, 2015		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 11,186,547

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2014-174062	Aug 28, 2014
Japan	2015-034729	Feb 25, 2015

International Family Members for US Patent 11,186,547

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	101695
Australia	2015309862
Brazil	112017002827
Canada	2957005